Obsidian Therapeutics to Merge with Galera and Raise $350 Million to Advance TIL Cell Therapy
Galera and Obsidian merge to form OBX, advancing TIL cancer therapy for melanoma & lung cancer, backed by $350M funding.
/ 47 items
#XY Event-Driven Stocks↓
Avanos Medical to Be Acquired by American Industrial Partners for $1.27 Billion
Avanos Medical is being bought by AIP for $1.27B in cash. Shareholders get $25 per share, a big premium. Company goes private in 2026.
Travere Wins Full FDA Approval for FILSPARI – First-Ever Treatment for Rare Kidney Disease FSGS
FDA approved FILSPARI for FSGS kidney disease, showing it lowers protein in urine and slows damage. It offers a new treatment option for patients with few choices.
Novo Nordisk Teams Up with OpenAI: AI Supercharges the Fight Against Obesity
Novo Nordisk teams with OpenAI to use AI for faster drug discovery, production and sales, aiming to catch rivals like Eli Lilly.
Mayo Clinic Partners with Sana Biotech: A Potential One-Shot Treatment for Type 1 Diabetes
Sana + Mayo Clinic are testing SC451, a cell therapy that may treat type 1 diabetes without daily insulin shots or immune drugs.
Pancreatic Cancer Breakthrough: New Daily Pill Nearly Doubles Survival in Major Trial
New drug daraxonrasib from Revolution Medicines doubled survival in pancreatic cancer (13.2 vs 6.7 months) and cut death risk by 60% in Phase 3.